3-溴-5-氟苯甲酸乙酯 | 353743-43-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-溴-5-氟苯甲酸乙酯
• 英文名称: ethyl 3-bromo-5-fluorobenzoate
• 英文别名: 3-bromo-5-fluoro-benzoic acid ethyl ester；3-bromo-5-fluorobenzoic acid ethyl ester；ethyl 3-bromo-5-fluoro-benzoate
• CAS: 353743-43-8
• 化学式: C₉H₈BrFO₂
• 分子量: 247.064
• InChiKey: NXLQOVWASVDMHM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-溴-5-氟苯甲酸乙酯 在 palladium diacetate 、 caesium carbonate 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 作用下， 以 二甲基亚砜 、 甲苯 为溶剂， 生成 3,5-Di-morpholin-4-yl-benzoic acid ethyl ester
  参考文献：
  名称：

  提高了苯胺的间氨基化和对称和不对称苯胺化的收率

  摘要：

  高得多的产率后较短的反应时间找到符合元在密封管中（180℃，5小时），例如哌啶和取代的苯的胺化在DMPU与微波加热米-fluorobenzonitrile 1得到米取代的3在92 ％ 屈服。这些改进的反应条件还以> 80％的收率提供了一种新的不对称二胺合成方法。

  DOI：

  10.1016/s0040-4039(01)00582-2
• 作为产物：
  描述：

  3-溴苯甲酸乙酯 在 (1,5-cyclooctadiene)(methoxy)iridium(I) dimer 、 1-fluoro-2,4,6-trimethylpyridinium hexafluorophosphate 、 (tBuCN)2Cu*OTf 、 silver fluoride 作用下， 以 四氢呋喃 为溶剂， 反应 36.0h， 生成 3-溴-5-氟苯甲酸乙酯
  参考文献：
  名称：

  Copper-Mediated Fluorination of Arylboronate Esters. Identification of a Copper(III) Fluoride Complex

  摘要：

  A method for the direct conversion of arylboronate esters to aryl fluorides under mild conditions with readily available reagents is reported. Tandem reactions have also been developed for the fluorination of arenes and aryl bromides through arylboronate ester intermediates. Mechanistic studies suggest that this fluorination reaction occurs through facile oxidation of Cu(I) to Cu(III), followed by rate-limiting transmetalation of a bound arylboronate to Cu(III). Fast C-F reductive elimination is proposed to occur from an aryl- copper(III)-fluoride complex. Cu(III) intermediates have been generated independently and identified by NMR spectroscopy and ESI-MS.

  DOI：

  10.1021/ja310909q

文献信息

• [EN] (2-((2-ALKOXY) -PHENYL) -CYCLOPENT-1-ENYL) AROMATIC CARBO AND HETEROCYCLIC ACID AND DERIVATIVES<br/>[FR] ACIDE (2-((2-ALCOXY) -PHENYL) -CYCLOPENT-1-ENYL) AROMATIQUE CARBOCYCLIQUE AND HETEROCYCLIQUE ET SES DERIVES
  申请人：GLAXO GROUP LTD

  公开号：WO2003084917A1

  公开（公告）日：2003-10-16

  Compounds of formula (I) or a pharmaceutically acceptable derivative thereof: (I) wherein A, R1 , R2 , Rx , R8 , R9 and n are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine.

  式(I)或其药学上可接受的衍生物的化合物：其中A、R1、R2、Rx、R8、R9和n如规范中所定义，一种制备这种化合物的方法，包括这种化合物的药物组合物以及这种化合物在医学上的用途。
• [EN] SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS<br/>[FR] COMPOSÉS DE SULFONAMIDE HÉTÉROCYCLIQUES SUBSTITUÉS UTILES COMME MODULATEURS DE TRPA1
  申请人：HOFFMANN LA ROCHE

  公开号：WO2015052264A1

  公开（公告）日：2015-04-16

  The invention is concerned with the compounds of formula I or II: and salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I or II as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.

  本发明涉及式I或II的化合物及其盐。此外，本发明还涉及制备这些化合物的方法以及使用这些化合物的方法，以及含有这些化合物的药物组合物。这些化合物可能对治疗由TRPA1介导的疾病和状况，如疼痛，具有用途。
• [EN] FLUORINATION OF ARYL COMPOUNDS<br/>[FR] FLUORATION DE COMPOSÉS ARYLES
  申请人：UNIV CALIFORNIA

  公开号：WO2014107379A1

  公开（公告）日：2014-07-10

  The invention provides compositions and methods of using the compositions in fluorinating aryl precursors containing a leaving group replaceable by a fluorine atom. The compositions include a metal ion source, a electrophilic fluorine source, a base, and a compound, which is an aryl precursor of the aryl fluoride, and which has a leaving group replaceable by the fluorine atom. Exemplary methods of the invention make use of such compositions and methods to prepare an aryl fluoride compound. In an exemplary embodiment, the electrophilic fluorine source is a source of 18F.

  这项发明提供了一种在含有可被氟原子取代的离去基团的芳基前体中进行氟化的组合物和使用这些组合物的方法。这些组合物包括金属离子源、亲电性氟源、碱和一种化合物，该化合物是芳基氟化物的芳基前体，并且具有可被氟原子取代的离去基团。该发明的示例方法利用这些组合物和方法来制备芳基氟化物。在一个示例实施方式中，亲电性氟源是18F的源。
• COMPOUND HAVING 6-MEMBERED AROMATIC RING
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP2253618A1

  公开（公告）日：2010-11-24

  An object of the present invention is to provide an agent for preventing or treating schizophrenia or the like, wherein the compound of the present invention has GPR52 agonist activity. [Means] A compound represented by the following formula (I) or salt thereof: wherein A represents -(CH2)n-CO-NRa- (n is an integer of 0 to 3) or -NRa-CO-, B represents a hydrogen atom, halogen atom, cyano group, hydroxy group, or the like, X1, X2, X3, and X4 represent the same or different -CRx=, or -N=, Y represents -O-, -S-, -S(O)-, -S(O)2-, or NRy-, Z represents a bond, methylene, or ethylene, Ar1 represents a five- to ten-membered aromatic ring (except for thiazole) which may be substituted with one or more substituents selected from halogen atoms, optionally halogenated C1-6 alkyl groups, and the like, Ar2 represents a five- to six-membered aromatic ring which may be substituted with one or more substituents selected from halogen atoms, optionally halogenated C1-6 alkyl groups, and the like, and which may be condensed with an optionally substituted five-to six-membered ring, and Ra, Rb, Rx, and Ry represent the same or different hydrogen atom, halogen atoms, or the like].

  本发明的一个目的是提供一种用于预防或治疗精神分裂症或类似疾病的药剂，其中本发明的化合物具有GPR52激动剂活性。[意味着]由以下式(I)表示的化合物或其盐：其中A代表-(CH2)n-CO-NRa-（n为0到3的整数）或-NRa-CO-，B代表氢原子，卤素原子，氰基，羟基等，X1，X2，X3和X4代表相同或不同的-CRx=或-N=，Y代表-O-，-S-，-S(O)-，-S(O)2-，或NRy-，Z代表键，亚甲基，或乙烯基，Ar1代表一个五至十元芳香环（除噻唑外），可以用一个或多个卤素原子、可选择的卤代C1-6烷基等取代基取代，Ar2代表一个五至六元芳香环，可以用一个或多个卤素原子、可选择的卤代C1-6烷基等取代基取代，可以与一个可选择的取代的五至六元环螯合，并且Ra、Rb、Rx和Ry代表相同或不同的氢原子、卤素原子等。
• [EN] CYCLOPENTENE COMPOUNDS<br/>[FR] COMPOSES DE CYCLOPENTENE
  申请人：GLAXO GROUP LTD

  公开号：WO2005037793A1

  公开（公告）日：2005-04-28

  Compounds of formula (I) or a pharmaceutically acceptable derivative thereof: wherein A, B, Z, R1, R2a, R2b, R8, R9, and Rx are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine.

  式（I）的化合物或其药用可接受的衍生物：其中A、B、Z、R1、R2a、R2b、R8、R9和Rx如规范中定义的那样，一种制备这种化合物的方法，包含这种化合物的药物组合物以及这种化合物在医学中的用途。